Shen J, et al. – Aim of this study is to evaluate the efficacy and safety of a new treatment modality, cellular immune therapy based on personalized peptide vaccination (PPV–DC–CTL) combined with radiotherapy, for treating advanced hepatocellular carcinoma (HCC). For patients with advanced HCC, radiotherapy combined with PPV–DC–CTL provides a new therapeutic strategy, which is well tolerated, safe, feasible and effective.